Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at Florida Capital Event
Curated by THEOUTPOST
On Thu, 7 Nov, 12:03 AM UTC
2 Sources
2 Sources
[1]
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event By Investing.com
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (Firefly, we, or the Company) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the Capital Event Management Conference being held at the JW Marriott Miami in Aventura, Florida on November 22-24, 2024. To schedule a one-on-one investor meeting with management, please contact your representatives at CEM or email KCSA Strategic Communications at Firefly@KCSA.com. About CEM CEM curates exclusive live events and virtual meetings where issuers and investors have unique opportunities to connect 1:1 and build lasting relationships. Since 2011 CEM has provided issuers a forum to raise capital, gain market support, save time & money, and build relationships with leading North American small cap investors. About Firefly Firefly (NASDAQ: AIFF) is an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network (LON:NETW) Analytics (BNAâ„¢) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNAâ„¢ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNAâ„¢, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome. Please visit https://fireflyneuro.com/ for more information.
[2]
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event - Firefly Neuroscience (NASDAQ:AIFF)
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") AIFF, an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the Capital Event Management Conference being held at the JW Marriott Miami in Aventura, Florida on November 22-24, 2024. To schedule a one-on-one investor meeting with management, please contact your representatives at CEM or email KCSA Strategic Communications at Firefly@KCSA.com. About CEM CEM curates exclusive live events and virtual meetings where issuers and investors have unique opportunities to connect 1:1 and build lasting relationships. Since 2011 CEM has provided issuers a forum to raise capital, gain market support, save time & money, and build relationships with leading North American small cap investors. About Firefly Firefly AIFF is an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network Analytics (BNAâ„¢) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNAâ„¢ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNAâ„¢, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome. Please visit https://fireflyneuro.com/ for more information. Investor Contact KCSA Strategic Communications Valter Pinto or Jack Perkins (212) 896-1254 Firefly@KCSA.com Media Contact KCSA Strategic Communications Raquel Cona, Vice President (516) 779-2630 Rcona@KCSA.com Market News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
Firefly Neuroscience, an AI company developing innovative brain health solutions, announces its participation in the 8th Annual Florida Capital Event. The company's FDA-cleared Brain Network Analytics technology aims to revolutionize diagnostics and treatment monitoring for neurological and mental disorders.
Firefly Neuroscience Announces Participation in Florida Capital Event
Firefly Neuroscience, Inc. (NASDAQ: AIFF), an innovative Artificial Intelligence (AI) company focused on improving brain health outcomes, has announced its participation in the upcoming Capital Event Management Conference. The event is scheduled to take place from November 22-24, 2024, at the JW Marriott Miami in Aventura, Florida 12.
Company Overview and AI-Powered Technology
Firefly Neuroscience specializes in developing cutting-edge solutions for patients with neurological and mental disorders. At the core of their offerings is the FDA-510(k) cleared Brain Network Analytics (BNAâ„¢) technology, which aims to revolutionize diagnostic and treatment monitoring methods for various conditions including depression, dementia, anxiety disorders, concussions, and ADHD 1.
The company's BNAâ„¢ technology leverages artificial intelligence and machine learning, drawing insights from Firefly's extensive proprietary database. This database comprises standardized, high-definition longitudinal electroencephalograms (EEGs) from over 17,000 patients, representing twelve disorders as well as clinically normal individuals 2.
Clinical Applications and Potential Impact
When used in conjunction with an FDA-cleared EEG system, BNAâ„¢ has the potential to provide clinicians with comprehensive insights into brain function. These insights could significantly enhance a clinician's ability to:
- Accurately diagnose mental and cognitive disorders
- Evaluate the most suitable therapy or drug to optimize patient outcomes 12
Commercial Launch and Target Markets
Firefly Neuroscience is currently in the process of launching BNAâ„¢ commercially. The company is targeting two primary markets:
- Pharmaceutical companies engaged in drug research and clinical trials
- Medical practitioners for clinical use 12
Investor Relations and Future Prospects
The company's participation in the Capital Event Management Conference presents an opportunity for potential investors to engage directly with Firefly's management. Interested parties can schedule one-on-one investor meetings through CEM representatives or by contacting KCSA Strategic Communications 12.
About Capital Event Management (CEM)
CEM, the organizer of the Florida Capital Event, has been facilitating connections between issuers and investors since 2011. The company specializes in curating exclusive live events and virtual meetings, providing a forum for companies to raise capital, gain market support, and build relationships with leading North American small cap investors 12.
Firefly's Market Position
As a NASDAQ-listed company (AIFF), Firefly Neuroscience represents an interesting intersection of artificial intelligence, neuroscience, and healthcare. With its FDA-cleared technology and a database built over 15 years, the company appears well-positioned to capitalize on the growing demand for innovative brain health solutions 12.
Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at October Investor Conferences
Firefly Neuroscience, an AI company specializing in brain health diagnostics, announces its participation in two major investor conferences in October 2024, highlighting its innovative Brain Network Analytics technology.
2 Sources
2 Sources
Firefly Neuroscience Secures $12.4 Million Financing to Advance AI-Powered Brain Health Technology
Firefly Neuroscience, an AI company focused on brain health solutions, has closed a financing deal of up to $12.4 million to support the commercialization of its FDA-cleared Brain Network Analytics technology.
2 Sources
2 Sources
Firefly Neuroscience's AI-Powered EEG Analytics Show Promise in Drug Development and Neuropsychiatric Care
Firefly Neuroscience's FDA-cleared BNAâ„¢ platform, utilizing AI and machine learning, demonstrates significant potential in providing objective measures for drug efficacy and cognitive changes in neuropharmacology and psychiatry.
2 Sources
2 Sources
Firefly Neuroscience Grants Inducement Shares to Executive Chairman, Highlighting AI-Driven Brain Health Solutions
Firefly Neuroscience, an AI company focused on brain health, announces an inducement grant to its Executive Chairman and discusses its innovative Brain Network Analytics technology.
2 Sources
2 Sources
Firefly Neuroscience Unveils AI-Powered Brain Age Biomarker Using FDA-Cleared BNAâ„¢ Platform
Firefly Neuroscience announces a breakthrough in assessing cognitive brain age using its FDA-cleared BNAâ„¢ technology, potentially revolutionizing early detection and monitoring of neurological disorders like Alzheimer's.
2 Sources
2 Sources
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
The Outpost
Keep in touch
© 2025 TheOutpost.AI All rights reserved